tbuckley/cabot-search huggingface dataset:
Differential response from neoadjuvant chemotherapy across breast cancer subtypes.
Authors: H. Jinno, S. Matsuda, T. Hayashida, M. Takahashi, M. Sakata, T. Ikeda, M. Mukai, Y. Kitagawa
Journal: Journal of Clinical Oncology (2010)

662 Background: Clinical trials suggest that sensitivity to chemotherapy differs across breast cancer subtypes. This study's purpose was to evaluate the clinical utility of breast cancer subtypes in the prediction of pathologic complete response (pCR) in a cohort of breast cancer patients receiving neoadjuvant chemotherapy (NACT). Methods: Patients with stage II/III breast cancer received 4 cycles of XT (capecitabine 1650 mg/m2 on days 1-14 and docetaxel 60 mg/m2 on day 8 every 3 weeks), followed by 4 cycles of FEC (fluorouracil 500 mg/m2, epirubicin 90 mg/m2, cyclophosphamide 500 mg/m2 on day 1 every 3 weeks). Immunohistochemical analysis of estrogen receptor (ER), progesterone receptor (PgR), HER2, epidermal growth factor receptor (EGFR), cytokeratin (ck) 5/6, and Ki67 was performed in core needle biopsy samples at baseline. Tumors were classified as luminal A (ER+ and/or PgR+, and Ki67 < 20%), luminal B (ER+ and PgR+, and Ki67 > 20%), HER2 (ER- PgR-, and HER2+), or triple-negative (ER-, PgR-, and HER2-). Triple-negative tumors with and without EGFR+ and/or ck 5/6+ were further classified as basal-like and non-basal-like TN (NBTN), respectively. Results: Twenty-four patients were classified as luminal A, 18 were luminal B, 10 were HER2, 12 were basal-like, and 9 were NBTN. The overall response rate was 91.8%, including a complete response in 29 patients and a partial response in 38 patients. The overall pCR rate was 15.1% (11/73). The highest pCR rate (33.3%) was observed in patients with basal-like tumors. In triple-negative patients, basal-like patients showed significantly higher pCR rate than NBTN patients (33.3% vs. 11.1%, p > 0.01). Patients with HER-2 subtype demonstrated the pCR rate of 30.0%. A higher proportion of luminal B patients had pCR than luminal A patients (16.6% vs. 4.1%, p > 0.02). With 33 months median follow-up, estimated 2-year disease-free survival for luminal A, luminal B, HER2, basal-like, and NBTN was 75.0%, 83.4%, 70%, 83.4%, and 88.9%, respectively. Conclusions: Our data indicate that breast cancer subtypes are useful predictive biomarkers of pCR in breast cancer patients treated with NACT. No significant financial relationships to disclose.
Bortezomib, Adriamycin Dexamethasone (PAD) Combination Therapies or Patients with Relapsed or Refractory Myeloma Previously Treated with VAD or VAD like Therapy.
Authors: Treen C. Morris, Mary Drake, Paul J. Kettle, Aishleen Brunton, James D. Cavenagh, Heather E. Oakervee, Michael O’Dwyer, Margaret Murray, Tanya O’Shea, Gordon Cook
Journal: Blood (2006)
Should We Abandon Routine Visits?
Authors: Daniel Pomerantz
Journal: Annals of Internal Medicine (2016)

Letters4 October 2016Should We Abandon Routine Visits?Daniel Pomerantz, MD, MPHDaniel Pomerantz, MD, MPHFrom Montefiore New Rochelle Hospital, New Rochelle, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0324 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Himmelstein and Phillips (1) acknowledge that the evidence against routine health checks is old and outdated. They also recognize that there may be other good reasons to continue having visits that are not based on the need for evaluation or treatment of a specific health condition. As a practicing primary care internist and a palliative medicine specialist, I see a great need for an ongoing series of visits with my patients to both follow up on their health and well-being but also facilitate an ongoing conversation about what is important to them. Some of these are explicit ...References1. Himmelstein DU, Phillips RS. Should we abandon routine visits? There is little evidence for or against. Ann Intern Med. 2016;164:498-9. [PMID: 26747523]. doi:10.7326/M15-2097 LinkGoogle Scholar2. Bruen BK, Ku L, Lu X, Shin P. No evidence that primary care physicians offer less care to Medicaid, community health center, or uninsured patients. Health Aff (Millwood). 2013;32:1624-30. [PMID: 24019368] doi:10.1377/hlthaff.2012.1300 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Montefiore New Rochelle Hospital, New Rochelle, New York.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0324. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoShould We Abandon Routine Visits? There Is Little Evidence for or Against David U. Himmelstein and Russell S. Phillips Should We Abandon Routine Visits? Stephen J. Gluckman Should We Abandon Routine Visits? Thomas J. Poulton Should We Abandon Routine Visits? David U. Himmelstein and Russell S. Phillips Should We Abandon Routine Visits? William R. Phillips Metrics 4 October 2016Volume 165, Issue 7Page: 528-529KeywordsCancer screeningChildrenColorectal cancerConflicts of interestDisclosureForecastingHealth careHealth care facilitiesPatient advocacyPatients ePublished: 4 October 2016 Issue Published: 4 October 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia
Authors: Emma I. Andersson, Takahiro Tanahashi, Nodoka Sekiguchi, Vanessa Rebecca Gasparini, Sabrina Bortoluzzi, Toru Kawakami, Kazuyuki Matsuda, Takeki Mitsui, Samuli Eldfors, Stefania Bortoluzzi, Alessandro Coppe, Andrea Binatti, Sonja Lagström, Pekka Ellonen, Noriyasu Fukushima, Sayaka Nishina, Noriko Senoo, Hitoshi Sakai, Hideyuki Nakazawa, Yok-Lam Kwong, Thomas P. Loughran, Jaroslaw P. Maciejewski, Satu Mustjoki, Fumihiro Ishida
Journal: Blood (2016)
EVOLUTION OF LUNG FUNCTION PARAMETERS IN A TRI-MODALITY PROTOCOL FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM): HOW SAFE IS INTENSITY-MODULATED RADIOTHERAPY?
Authors: Yolande Lievens, Philippe Nafteux, Barbara Vanstraelen, Johnny Moons, Kristiaan Nackaerts
Journal: Journal of Thoracic Oncology (2008)
Impact of HLA Class I and Class II DNA High-Resolution HLA Typing on Outcome in Adult Unrelated Stem Cell Transplantation after In Vivo T-Cell Depletion with CAMPATH 1H: A Single Centre Experience in 100 Patients.
Authors: Jolanta B. Perz, Ruhena Sergeant, Richard Szydlo, Nick Davey, Eduardo Olavarria, Jane F. Apperley
Journal: Blood (2005)
Carcinologic resection of abdominal tumors involving retroperitoneal vessels: Results of a synergical multidisciplinary approach between oncologic and vascular surgical teams.
Authors: F. Quenet, P. Alric, F. Iborra, L. Roca, T. D'Annoville, P. Colombo, F. Joyeux, B. Saint-Aubert, C. Marty-Ane, P. Rouanet
Journal: Journal of Clinical Oncology (2010)

e20521 Background: Abdominal tumors involving retroperitoneal vessels are rare but often constitute a terminal condition because of the presumed inextirpability of the tumor. In order to address these technical difficulties, a surgical task group was formed by experienced oncological and vascular surgeons. Methods: 69 patients with abdominal or retroperitoneal tumors involving vessels presumed on preoperative imaging data, have been retrospectively reviewed from June 2000 to December 2009. A systematic assessment of the resecability had been done for every case preoperatively with both the oncologic and the vascular surgeon to plan an operative strategy. Median age was 50,5 years old. Major histologic subtypes were retroperitoneal sarcoma (n = 26; 38%), lymph node metastasis of testicular germ cell tumor, (n = 17; 25%), endocrine tumors (n = 10; 14%), renal cell carcinoma (n = 5; 7%), adrenal tumors (n = 3; 4%). Results: 60 patients underwent a resection of their tumor. In 9 cases, the tumor was considered inextirpable at laparotomy. Complete resection was performed to guarantee clear margins: R0 in 45 patients (75%), R1 in 12 (20%). A gross residual tumor was left behind in 3 cases R2 (5%). The main vessels involved were the inferior vena cava (n = 35; 50%), iliac axis (n = 11; 16%), abdominal aorta (n = 12; 17%) and superior mesenteric artery (n = 4; 6%). The conservation of these vessels was possible in 21 (30%) cases. In 31 (45%) other cases a graft replacement was required. There was no operative mortality and one patient died postoperatively because of pulmonary embolism. The global morbidity rate was 27%. The overall survival rate at 24 months was 76.5%, 95%CI (58.51-87.43). Conclusions: This particular approach of four hands surgery should constitute a new paradigm in the field of surgical resection of tumors with retroperitoneal vascular involvement. The synergies provided by a joint oncological and vascular approach have a positive impact on local control of the disease, improving the resecability rate and the operative safety in association with a low morbidity rate. No significant financial relationships to disclose.
MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease
Authors: Gareth J Morgan, Faith E Davies, Walter M Gregory, Sue E Bell, Alex J Szubert, Gordon Cook, Mark T Drayson, Roger G Owen, Fiona M Ross, Graham H Jackson, J. Anthony Child
Journal: Blood (2011)
Guillain–Barré Syndrome Associated with Zika Virus Infection in Colombia
Authors: Beatriz Parra, Jairo Lizarazo, Jorge A. Jiménez-Arango, Andrés F. Zea-Vera, Guillermo González-Manrique, José Vargas, Jorge A. Angarita, Gonzalo Zuñiga, Reydmar Lopez-Gonzalez, Cindy L. Beltran, Karen H. Rizcala, Maria T. Morales, Oscar Pacheco, Martha L. Ospina, Anupama Kumar, David R. Cornblath, Laura S. Muñoz, Lyda Osorio, Paula Barreras, Carlos A. Pardo
Journal: New England Journal of Medicine (2016)

Zika virus (ZIKV) infection has been linked to the Guillain-Barré syndrome. From November 2015 through March 2016, clusters of cases of the Guillain-Barré syndrome were observed during the outbreak of ZIKV infection in Colombia. We characterized the clinical features of cases of Guillain-Barré syndrome in the context of this ZIKV infection outbreak and investigated their relationship with ZIKV infection.A total of 68 patients with the Guillain-Barré syndrome at six Colombian hospitals were evaluated clinically, and virologic studies were completed for 42 of the patients. We performed reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays for ZIKV in blood, cerebrospinal fluid, and urine, as well as antiflavivirus antibody assays.A total of 66 patients (97%) had symptoms compatible with ZIKV infection before the onset of the Guillain-Barré syndrome. The median period between the onset of symptoms of ZIKV infection and symptoms of the Guillain-Barré syndrome was 7 days (interquartile range, 3 to 10). Among the 68 patients with the Guillain-Barré syndrome, 50% were found to have bilateral facial paralysis on examination. Among 46 patients in whom nerve-conduction studies and electromyography were performed, the results in 36 patients (78%) were consistent with the acute inflammatory demyelinating polyneuropathy subtype of the Guillain-Barré syndrome. Among the 42 patients who had samples tested for ZIKV by RT-PCR, the results were positive in 17 patients (40%). Most of the positive RT-PCR results were in urine samples (in 16 of the 17 patients with positive RT-PCR results), although 3 samples of cerebrospinal fluid were also positive. In 18 of 42 patients (43%) with the Guillain-Barré syndrome who underwent laboratory testing, the presence of ZIKV infection was supported by clinical and immunologic findings. In 20 of these 42 patients (48%), the Guillain-Barré syndrome had a parainfectious onset. All patients tested were negative for dengue virus infection as assessed by RT-PCR.The evidence of ZIKV infection documented by RT-PCR among patients with the Guillain-Barré syndrome during the outbreak of ZIKV infection in Colombia lends support to the role of the infection in the development of the Guillain-Barré syndrome. (Funded by the Bart McLean Fund for Neuroimmunology Research and others.).
Harness shared data in international Zika registry
Authors: David Baud, Patrick Gérardin, Audrey Merriam, Marco P Alves, Didier Musso, Blaise Genton, Alice Panchaud
Journal: BMJ (2016)

à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Prospective, Randomized, Multicenter Study Comparing Antithymocyte Globulin (ATG) Alone with ATG Plus Cyclosporine (CsA) for Treatment of Children with Nonsevere Aplastic Anemia (nSAA).
Authors: Hiroshi Yagasaki, Hiromasa Yabe, Hiroshi Ayukawa, Yasushi Noguchi, Osamu Ijichi, Ryoji Kobayashi, Masahiro Tsuchida, Hideo Mugishima, Akira Ohara, Akira Morimoto, Shouichi Oga, Fumio Bessho, Tatsutoshi Nakahata, Ichiro Tsukimoto, Seiji Kojima
Journal: Blood (2005)
Assessing the Exposome with External Measures: Commentary on the State of the Science and Research Recommendations
Authors: Michelle C. Turner, Mark Nieuwenhuijsen, Kim Anderson, David Balshaw, Yuxia Cui, Genevieve Dunton, Jane A. Hoppin, Petros Koutrakis, Michael Jerrett
Journal: Annual Review of Public Health (2017)

The exposome comprises all environmental exposures that a person experiences from conception throughout the life course. Here we review the state of the science for assessing external exposures within the exposome. This article reviews (a) categories of exposures that can be assessed externally, (b) the current state of the science in external exposure assessment, (c) current tools available for external exposure assessment, and (d) priority research needs. We describe major scientific and technological advances that inform external assessment of the exposome, including geographic information systems; remote sensing; global positioning system and geolocation technologies; portable and personal sensing, including smartphone-based sensors and assessments; and self-reported questionnaire assessments, which increasingly rely on Internet-based platforms. We also discuss priority research needs related to methodological and technological improvement, data analysis and interpretation, data sharing, and other practical considerations, including improved assessment of exposure variability as well as exposure in multiple, critical life stages.
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST)
Authors: H. Dumez, P. Reichard, J. Y. Blay, P. Schöffski, J. A. Morgan, I. L. Ray-Coquard, N. Hollaender, A. Jappe, G. D. Demetri
Journal: Journal of Clinical Oncology (2008)

10519 Background: Primary resistance to imatinib in pts with advanced GIST is uncommon but after durable benefit, most pts eventually develop secondary resistance. Molecular pathways of resistance may activate alternate oncogenic signaling mechanisms, including the AKT/mTOR pathway. Synergism in vitro between imatinib and RAD001 has been shown in human GIST cell lines resistant to imatinib, serving as the basis for this phase I/II trial. Phase 1 results were reported previously. This abstract reports phase 2 results. Methods: Study follows a Simon's 2-stage design. Patients were enrolled into one of two strata. Stratum 1 (1st-line failures): pts with progressive GIST on imatinib only (at least 4 mos treatment). Stratum 2 (post-2nd-line): patients with progressive GIST following imatinib and further therapies (e.g. sunitinib, investigational drugs) of which most pts received sunitinib. Main efficacy variable was 4 mo progression-free survival (PFS) with the criterion of interest being a 4 mo PFS rate of 20%, implying that at least 5/41 pts should be nonprogressive (α 0.046, 90% power). The passage from Simon stage 1 to 2 was dependent on a 4mo PFS rate of at least 5%, implying a 4 mo PFS in ≥ 2/21 pts. Each stratum was analyzed separately, but with the same criteria. All patients received imatinib 600 mg/d and RAD001 2.5 mg/d. The analysis was based on RECIST per investigator assessment. Results: Stratum 1: 23 of 28 enrolled pts (82.1%) were evaluable for 4 mo PFS, where 4 pts (17.4 %) were progression-free. Despite the criterion for continuing to stage 2 was met it was decided not to continue into stage 2 due to availability of new alternative treatment options. Stratum 2: 35 of 47 enrolled pts (74.5%) were evaluable for 4 mo PFS, where 13 pts (37.1 %) were progression-free. Conclusions: The results suggest that GIST pts may benefit from combined treatment in case of 1st- and 2nd-line treatment failure. However, randomized studies are needed to demonstrate the benefit associated with the combined therapy. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novartis Amgen, Bayer, GlaxoSmithKline, Novartis, Pfizer, PharmaMar Novartis GlaxoSmithKline, Novartis, Pfizer, PharmaMar Amgen, Bristol-Myers Squibb, Infinity, Novartis, OSI, Pfizer Infinity, Novartis, Pfizer Novartis
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives
Authors: R. Costa, B.A. Carneiro, D.A. Wainwright, C.A. Santa-Maria, P. Kumthekar, Y.K. Chae, W.J. Gradishar, M. Cristofanilli, F.J. Giles
Journal: Annals of Oncology (2016)
Nutrition for the ageing brain: Towards evidence for an optimal diet
Authors: David Vauzour, Maria Camprubi-Robles, Sophie Miquel-Kergoat, Cristina Andres-Lacueva, Diána Bánáti, Pascale Barberger-Gateau, Gene L. Bowman, Laura Caberlotto, Robert Clarke, Eef Hogervorst, Amanda J. Kiliaan, Ugo Lucca, Claudine Manach, Anne-Marie Minihane, Ellen Siobhan Mitchell, Robert Perneczky, Hugh Perry, Anne-Marie Roussel, Jeroen Schuermans, John Sijben, Jeremy P.E. Spencer, Sandrine Thuret, Ondine van de Rest, Maurits Vandewoude, Keith Wesnes, Robert J. Williams, Robin S.B. Williams, Maria Ramirez
Journal: Ageing Research Reviews (2016)

As people age they become increasingly susceptible to chronic and extremely debilitating brain diseases. The precise cause of the neuronal degeneration underlying these disorders, and indeed normal brain ageing remains however elusive. Considering the limits of existing preventive methods, there is a desire to develop effective and safe strategies. Growing preclinical and clinical research in healthy individuals or at the early stage of cognitive decline has demonstrated the beneficial impact of nutrition on cognitive functions. The present review is the most recent in a series produced by the Nutrition and Mental Performance Task Force under the auspice of the International Life Sciences Institute Europe (ILSI Europe). The latest scientific advances specific to how dietary nutrients and non-nutrient may affect cognitive ageing are presented. Furthermore, several key points related to mechanisms contributing to brain ageing, pathological conditions affecting brain function, and brain biomarkers are also discussed. Overall, findings are inconsistent and fragmented and more research is warranted to determine the underlying mechanisms and to establish dose-response relationships for optimal brain maintenance in different population subgroups. Such approaches are likely to provide the necessary evidence to develop research portfolios that will inform about new dietary recommendations on how to prevent cognitive decline.
Patients' willingness to be informed on cancer clinical trials.
Authors: I. Pauporte, E. Manach, M. Duperray, N. Thammavong, N. Bachouche, A. Hommais
Journal: Journal of Clinical Oncology (2010)

6100 Background: Cancer patients' willingness to be informed about clinical trials (CT) and their investigation sites is rapidly increasing. This information must be delivered in patients' native language. The French NCI (INCa) has created a national registry for clinical trials in oncology (Registre Essais Cliniques Français - RECF www.e-cancer.fir). No public information campaign has been lead and data on patients' frequentation and expectancies are not available. Methods: From February 27 to August 27 2009, visitors (patients or relatives) of the INCa's CT-dedicated website were asked to complete an anonymous questionnaire. Data on gender, type of cancer, time from diagnosis, knowledge about clinical research, CT participation, and quality of information delivered by the RECF, were collected. Results: A total of 319 questionnaires were completed. The majority of the participants were women (211, 66%) even after adjustment for gender-specific cancers (148, 63%). Of them: 193 (61%) were patients; 293 (92%) knew the primary site of the disease they were looking for information; 269 (85%) knew if it was a localized (47%) or a distant disease (38%); 206 (65%) and 235 (74%) had heard the terms “clinical research” and “CT”, respectively. A third (36%) of patients and 21% of relatives had been offered to participate to a CT; 58/70 (83%) of patients invited to participate to a CT had agreed to. Three fourth of (76%) participants had discovered RECF by Internet browsing; a third of them (28%) visiting INCa's website. Most of participants, 81%, (88% of patients) found the information useful and 88% (89% of patients) comprehensible. About half (52%) of participants were looking for CT of interest to participate, 42% for general information on CT, 54% for CT on innovative drugs, 45% the list of care centres proposing CT. Publication of CT results was asked in 8/68 (12%) of participants' comments. Conclusions: Participants of this survey seemed to be well informed about their cancer and the existence of CT. They seemed satisfied by the quality and readability of information provided by RECF. Updated data on CT was commonly searched. Public information campaigns on CT and specific interventions including updated lists of hospitals of running CT have to be promoted. No significant financial relationships to disclose.
First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus
Authors: Elisa Petruccioli, Teresa Chiacchio, Ilaria Pepponi, Valentina Vanini, Rocco Urso, Gilda Cuzzi, Lucia Barcellini, Daniela Maria Cirillo, Fabrizio Palmieri, Giuseppe Ippolito, Delia Goletti
Journal: Journal of Infection (2016)

QuantiFERON®-TB Gold Plus (QFT-Plus) is the new generation of QuantiFERON-TB Gold In-Tube test to identify latent tuberculosis infection (LTBI). QFT-Plus includes TB1 and TB2 tubes which contain selected Mycobacterium tuberculosis (Mtb) peptides designed to stimulate both CD4 and CD8 T-cells. Aim of this study is the flow cytometric characterization of the specific CD4 and CD8 T-cell responses to Mtb antigens contained within QFT-Plus.We enrolled 27 active tuberculosis (TB) patients and 30 LTBI individuals. Following stimulation with TB1 and TB2, antigen-specific T-cells were characterized by flow cytometry. Data were also correlated with the grade of TB severity.TB1 mainly elicited a CD4 T-cell response while TB2 induced both CD4 and CD8 responses. Moreover, the TB2-specific CD4 response was detected for both active TB and LTBI patients, whereas the TB2-specific CD8 response was primarily associated with active TB (p = 0.01).To our knowledge, we report the first characterization of the CD4 and CD8 T-cell response to QFT-Plus. CD8 T-cell response is mainly due to TB2 stimulation which is largely associated to active TB. These results provide a better knowledge on the use of this assay.